Research and Development to Accelerate New Drug Development and Gene-sequencing
Advancements in technology and medical science have played a key role in the development of new treatments and therapies for an array of disorders and diseases. Conventionally, primary immunodeficiencies have been predominantly characterized as per the immunologic phenotype. Research and development activities within the primary immunodeficiency market are largely focused on the discovery of human genes that could cause primary immunodeficiency. More recently, four distinct genetic defects that could potentially lead to primary immunodeficiency diseases and acute congenital neutropenia continue to drive research in the primary immunodeficiency market.
Some of the key areas within the primary immunodeficiency market that are currently being investigated include the role of follicular T cells in the development of antibody responses, the link between impaired B-cell maturation and inflammatory conditions, inflammatory and autoimmune manifestations, and recently discovered gene defects. Moreover, several researchers are exploring the overall efficacy of the lentiviral vector-mediated gene therapies in patients that are suffering from adenosine deaminize-deficient severe combined immunodeficiency (SCID). Over the past decade, the management of primary immunodeficiency has advanced at a rapid pace due to a surge in investments and focus on research. Strides taken by sequencing, gene-editing tools, and the development of new drugs are expected to boost the prospects of the market for primary immunodeficiency during the forecast period. At the back of these factors, the global primary immunodeficiency market is expected to attain reach a value of ~US$ 9.9 Bn by the end of 2028.
To know the scope of our report Get a Sample on Primary Immunodeficiency Market
Advancements in Genetic Management and Next-generation Sequencing Technologies to Aid Market Growth
One of the most common symptomatic primary immunodeficiency disorders that continues to attract investments and research include the common variable immunodeficiency disorder. The onset of genome sequencing and soaring interest in genome-wide association studies have played a key role in enhancing and understanding the overall genetics of common variable primary immunodeficiency. Research has also opened up new frontiers as far as understanding the pathogenesis of common variable primary immunodeficiency. In recent times, the adoption of DNA sequencing, RNA sequencing, epigenetic, and proteomic profiles is on the rise to assess common variable primary immunodeficiency that is linked with disease pathways and other therapeutic targets. Scientists and researchers are increasingly focusing on understanding the genetics of primary immunodeficiency.
Get a glimpse of the in-depth analysis through our Report Brochure
The prevalence of primary immunodeficiency around the world is on the rise due to which, the demand for novel treatments and therapies has witnessed considerable growth. Significant progress in sequencing technologies is triggered by the discovery of a range of monogenic forms of common variable primary immunodeficiency. Over the past decade, due to advancements in technology and research, participants of the primary immunodeficiency market are swaying toward the use of omics-based technologies and integrating next-generation platforms in the common variable primary immunodeficiency space.
Advancements in Molecular Techniques Open up New Treatment Alternatives for Primary Immunodeficiency Disorders
Over the past few decades, inborn errors of immunity (IEIs) have witnessed exponential growth. In addition, over 400 glaring defects have been listed in the recently amended International Union of Immunological Societies (IUIS). In the past few years, due to considerable information pertaining to new genes and diseases, the primary immunodeficiency market is set to witness notable development and likely to emphasize on the concept of “inborn errors of immunity” as a collective group of various phenotypes such as infection, autoimmunity, autoinflammation, malignancy, allergy, etc. Developments in molecular studies have streamlined the detection of an array of potential targets for certain therapeutic interventions. Targeted therapies constitute small molecules and monoclonal antibodies, including cytokine inhibitors and cytokines. Some of the most popular and extensively used targeted therapies include rituximab— a therapy deployed to cater to issues related to autoimmune and lymph proliferative manifestations. Apart from noteworthy developments in molecular studies, gene therapies have also gained a great amount of popularity over the past three decades. The adoption of gene therapy in the primary immunodeficiency market has increased at a consistent pace since the 1990s, particularly to address X-SCID and ADA-SCID.
Although developments in molecular studies are expected to augment the market for primary immunodeficiency, companies in the current market landscape are expected to overcome a few major roadblocks, including increasing the availability of different diagnostic tools and treatments to patients across the world and offering customized treatments cost-effectively.
Expanding operations in future? To get the perfect launch ask for a custom report
More Trending Reports by Transparency Market Research - https://www.biospace.com/article/meningococcal-vaccines-market-to-touch-us-9-billion-by-2026-tmr/
Comments
Post a Comment